Modafinil: A review of its pharmacology and clinical efficacy in the management of narcolepsy

CNS Drugs

Volumn 9, Issue 4, 1998, Pages 311-324

  McClellan, Karen J ^a   Spencer, Caroline M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRACEPTIVE AGENT; DEXAMPHETAMINE; EPHEDRINE; METHYLPHENIDATE; MODAFINIL; PEMOLINE;

CATAPLEXY; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ABUSE; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; INFECTION; MALE; MULTICENTER STUDY; NARCOLEPSY; NEUROLOGIC DISEASE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; WAKEFULNESS;

EID: 0031893206     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199809040-00006     Document Type: Review

References (63)

1. Tanganelli S, Fuxe K, Ferraro L, et al. Inhibitory effects of the psychoactive drug modafinil on γ-aminobutyric acid outflow from the cerebral cortex of the awake freely moving guinea-pig. Possible involvement of 5-hydroxytryptamine mechanisms. Naunyn Schmiedebergs Arch Pharmacol 1992 Apr: 345: 461-5
2. Tanganelli S, Pérez de la Mora M, Ferraro L, et al. Modafinil and cortical τ-aminobutyric acid outflow. Modulation by 5-hydroxytryptamine neurotoxins. Eur J Pharmacol 1995 Jan 24; 273: 63-71
3. Ferraro L, Tanganelli S, O'Connor WT, et al. The vigilance promoting drug modafinil increases dopamine release in the rat nucleus accumbens via the involvement of a local GABA-ergic mechanism. Eur J Pharmacol 1996 Jun 13; 306: 33-9
4. 3 receptor. Neurosci Lett 1996 Dec 6; 220: 5-8
5. De Séréville JE, Boer C, Rambert FA, et al. Lack of pre-synaptic dopaminergic involvement in modafinil activity in anaesthetized mice: in vivo voltammetry studies. Neuropharmacology 1994 Jun; 33: 755-61
6. Duteil J, de Séréville J-E, Boer C, et al. Lack of dopaminergic involvement in modafinil, but not amphetamine and methylphenidate, activity in anaesthetized mice and rats: in vivo voltammetry studies [abstract]. Eur J Pharmacol 1990 Jul; 183: 1406-7
7. Mignot F, Nishino S, Guilleminault C, et al. Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep 1994 Aug; 17: 436-7
8. Ferraro L, Antonelli T, O'Connor WT, et al. Modafinil: an anti-narcoleptic drug with a different neurochemical profile to d-amphetamine and dopamine uptake blockers. Biol Psychiatry 1997 Dec; 42: 1181-3
9. Lin J-S, Hou Y, Jouvet M. Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cat. Proc Natl Acad Sci U S A 1996 Nov 26; 91: 14128-33
10. 1-adrenergic stimulation in relation to the behaviour stimulating effect of modafinil: studies with experimental animals. Eur J Pharmacol 1990 May 3; 180: 49-58
11. Hermant J-F, Rambert FA, Duteil J. Awakening properties of modafinil: effect on nocturnal activity in monkeys (Macacamulatta) after acute and repeated administration. Psychopharmacology 1991; 103 (1): 28-32
12. Lin JS, Roussel B, Akaoka H, et al. Role of catecholamines in the modafinil and amphetamine induced wakefulness, a comparative pharmacological study in the cat. Brain Res 1992 Sep 25; 591: 319-26
13. Rambert FA, Pessonnier J, Duteil J. Modafinil-, amphetamine-and methylphenidate-induced hyperactivities in mice involve different mechanisms. Eur J Pharmaeol 1990; 183 (2): 455-6
14. 1H-NMR study. Brain Res 1995 Sep 25; 693: 251-6
15. Ueki A, Rosén L, Andbjer B, et al. Evidence for a preventive action of the vigilance-promoting drug modafinil against striatal ischemic injury induced by endothelin-1 in the rat. Exp Brain Res 1993 Sep; 96: 89-99
16. Fuxe K, Janson AM, Rosén L, et al. Evidence for a protective action of the vigilance promoting drug modafinil on the MPTP-induced degeneration of the nigrostriatal dopamine neurons in the black mouse: an immunocytochemical and biochemical analysis. Exp Brain Res 1992; 88: 117-30
17. Ueki A, Rosén L, Andbjer B, et al. The vigilance-promoting drug modafinil counteracts the reduction of tyrosine hydroxylase immunoreactivity and of dopamine stores in nigro-striatal dopamine neurons in the male rat after a partial transection of the dopamine pathway. Exp Brain Res 1993; 93: 259-70
18. Lagarde DPS, Anton G. Comparative study of stimulant effects of d-amphetamine sulfate and modafinil, an original psychostimulant [abstract]. Eur J Pharmacol 1990 Jul; 183: 1476
19. Lagarde D. Effects of modafinil on the nocturnal activity and behavioural sleep of Rhesus monkeys (Maccaca mulatta). Med Sci Res 1990 May 16-31; 18: 397-9
20. Lagarde D, Milhaud C. Electroencephalographic effects of modafinil, an alpha-1- adrenergic psychostimulant, on the sleep of rhesus monkeys. Sleep 1990 Oct: 13: 441-8
21. Touret M, Sallanon-Moulin M, Jouvet M. Awakening properties of modafinil without paradoxical sleep rebound: comparative study with amphetamine in the rat. Neurosci Lett 1995 Apr 7; 189: 43-6
22. Adrien J, Lebrand C, Maudhuit C. Effects of modafinil on wakefulness and sleep in the rat [abstract]. J Sleep Res 1994 Jun; 3 Suppl. 1: 2
23. Edgar DM, Seidel WF, Contreras PC, et al. Modafinil promotes EEG wake without intensifying motor activity in the rat [abstract]. Can J Physiol Pharmacol 1994; 72 Suppl. 1: 362
24. Edgar DM, Seidel WF. Modafinil induces wakefulness without intensifying motor activity or subsequent rebound hypersomnolence in the rat. J Pharmacol Exp Ther 1997 Nov; 283: 757-69
25. Shelton J, Nishino S, Vaught J, et al. Comparative effects of modafinil and amphetamine on daytime sleepiness and cataplexy of narcoleptic dogs. Sleep 1995 Dec; 18: 817-26
26. Panckeri KA, Schotland HM, Pack AI, et al. Modafinil decreases hypersomnolence in the English bulldog, a natural animal model of sleep-disordered breathing. Sleep 1996 Oct; 19: 626-31
27. Rambert FA, Pessonnier J, Autran L, et al. Intracerebroventricular injected MODAFINIL (but not its main metabolites, acid and sulfone) induces hyperlocomotor activity in mice [abstract]. Neuropsychopharmacology 1994 May; 10 (3S/Pt 2): 169S
28. Simon P, Hémet C, Costentin J. Analysis of stimulant locomotor effects of modafinil in various strains of mice and rats. Fundam Clin Pharmacol 1996; 10 (5): 431-5
29. Moachon G, Rambert FA, Matinier D, et al. Modafinil plasma levels are correlated to locomotor effect in mice [abstract]. Therapie 1990 Jan-Feb; 45: 79
30. Hermant JF, Rambert FA, Duteil J. Lack of cardiovascular effects after administration of modafinil in conscious monkeys [abstract]. Fundam Clin Pharmacol 1991; 5: 825
31. Saletu B, Frey R, Krupka M, et al. Differential effects of a new central adrenergic agonist - modafinil - and d-amphetamine on sleep and early morning behaviour in young healthy volunteers. Int J Clin Pharmacol Res 1989; 9 (3): 183-95
32. Saletu B, Frey R, Krupka M, et al. Differential effects of the new central adrenergic agonist modafinil and d-amphetamine on sleep and early morning behaviour in elderlies. Arzneimittel Forshung 1989 Oct; 39: 1268-73
33. Baranski JV, Pigeau RA. Self-monitoring cognitive performance during sleep deprivation: effects of modafinil, d-amphetamine and placebo. J Sleep Res 1997; 6: 84-91
34. Pigeau R, Naitoh P, Buguet A, et al. Modafinil, d-amphetamine and placebo during 64 hours of sustained mental work. I. Effects on mood, fatigue, cognitive performance and body temperature. J Sleep Res 1995; 4 (4): 212-28
35. Lagarde D, Batejat D, Van Beers P, et al. Interest of modafinil, a new psychostimulant, during a sixty-hour sleep deprivation experiment. Fundam Clin Pharmacol 1995; 9 (3): 271-9
36. Bensimon G, Benoit D, Lacomblez L, et al. Antagonism by modafinil of the psychomotor and cognitive impairment induced by sleep-deprivation in 12 healthy volunteers. Eur Psychiatry 1991; 6 (2): 93-7
37. Buguet A, Montmayeur A, Pigeau R, et al. Modafinil, d-amphetamine and placebo during 64 hours of sustained mental work. II. Effects on two nights of recovery sleep. J Sleep Res 1995; 4 (4): 229-41
38. Gold LH, Balster RL. Evaluation of the cocaine-like discriminative stimulus effects and reinforcing effects of modafinil. Psychopharmacology 1996 Aug; 126: 286-92
39. Warot D, Corruble E, Payan C, et al. Subjective effects of modafinil, a new central adrenergic stimulant in healthy volunteers: a comparison with amphetamine, caffeine and placebo Eur Psychiatry 1993; 8 (4): 201-8
40. Jasinski DR. An evaluation of the abuse potential of modafinil using methylphenidate as a reference [poster]. CPDD: 1997 Jun; Nashville
41. Moachon G, Kanmacher I, Clenet M, et al. Pharmacokinetic profile of modafinil. Drugs Today 1996 Jun; 32: 327-37
42. Civil RH, Gorman SH, Strong DB, et al. Safety, tolerance and pharmacokinetics of single doses of modafinil in healthy subjects [abstract]. 9th Annual Meeting Sleep Research Society: 1995 May 30: Nashville, 49
43. Gorman SH, Neidlinger SK, Stong DB, et al. Pharmacokinetic profiles of modafinil and modafinil acid during a double-blind, ascending dose, seven-day administration of modafinil tablets in normal male subjects [abstract]. ISSX Proc 1994; 6: 75
44. Moachon G, Matinier D, Lubin S, et al. Pharmacokinetics of multiple doses of modafinil in hepatic insufficiency [abstract]. Can J Physiol Pharmacol 1994; 72 Suppl. 1: 303
45. Broughton RJ, Fleming JAE, George CFP, et al. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology 1947 Aug; 49: 444-51
46. Besset A, Chetrit M, Carlander B, et al. Use of modafinil in the treatment of narcolepsy: a long term follow-up study. Neurophysiol Clin 1996; 26: 60-6
47. Billiard M, Besset A, Montplaisir J, et al. Modafinil: a double-blind multicentric study. Sleep 1994 Dec; 17 Suppl.: S107-12
48. Boivin DB, Montplaisir J, Petit D, et al. Effects of modafinil on symptomatology of human narcolepsy. Clin Neuropharmacol 1993 Feb; 16: 46-53
49. Laffont F, Agar N, Mayer G, et al. Effect of modafinil in narcoleptic patients. Electrophysiologic and psychometric studies [in French]. Neurophysiol Clin 1995; 25: 84-95
50. Carpenter V, Barone Kribbs N, for the US Modafinil Multicenter Study Group. Self-reported and manifest sleepiness during blind withdrawal from modafinil in patients with narcolepsy [poster]. European Federation of Neurological Societies: 1997 Jun 4-8: Prague
51. US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. Ann Neurol 1998; 43: 88-97
52. Laffont F, Mayer G, Minz M. Modafinil in diurnal sleepiness. A study of 123 patients. Sleep 1994 Dec; 17 (8 Suppl.): S113-5
53. Bastuji H, Jouvet M. Successful treatment of idiopathic hypersomnia and narcolepsy with modafinil. Prog Neuropsychopharmacol Biol Psychiatry 1988; 12: 695-700
54. Laffont F, Agar N, Mayer G, et al. Modafinil in narcoleptic patients: electrophysiological and psychometric analysis [abstract]. J Sleep Res 1994; Jun; 3 Suppl. 1: 135
55. Walsleben JA, Beusterien KM, Walls M, et al. Modafinil improves health-related quality of life (HQL) in narcolepsy [abstract]. British Sleep Society Meeting 1997
56. Mitler MM, Hajdukovic R. Relative efficacy of drugs for the treatment of sleepiness in narcolepsy. Sleep 1991 Jun; 14: 218-20
57. Laboratoire L, Lafon. Modafinil. Vidal. Paris: Editions du Vidal, 1997
58. Monthly Index of Medical Specialities (MIMS). Mar 1998 ed. London: Haymarkel Medical Ltd, 1998
59. Diagnostic Classification Steering Committee. Thorpy MJ (chairman). The International Classification of Sleep Disorders: diagnostic and coding manual. Rochester (MN): American Sleep Disorders Association, 1990
60. Hublin C, Kaprio J, Partinen M, et al. The prevalence of narcolepsy: an epidemiological study of the Finnish twin cohort. Ann Neurol 1994; 35: 709-16
61. Broughton WA, Broughton RJ. Psychosocial impact of narcolepsy. Sleep 1994 (17): S45-9
62. Aldrich MS. Narcolepsy. Neurology 1992 Jul; 42 Suppl. 6: 34-43
63. Hublin C. Narcolepsy: current drug treatment options. CNS Drugs 1996; 5 (6): 426-36